Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › BCTX

BriaCell Therapeutics

BCTX Lead: Phase 3 7 Biotech Distilled articles ↓ 18 filings & releases ↓ Cash $9.9M (Jul 31, 2026) ↓ 7 verdicts ↓ 1 timing quote ↓
Oncology CellProtein

Market cap $34.5M 8.7M shares (10-K, Oct 28, 2026) × $3.95 close Nov 6, 2026

Most recent annual filing: 2026-10-28

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. Bria-IMT + CPI Ph3 interim2026Bria-IMT + CPI Ph3 interim, 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Technology platforms

TILsRx

Proprietary platform designed to activate tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment; integrates T cell engagers and immune checkpoint modulators; multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets; focus areas include prostate, lung, breast, pancreatic, and ovarian cancers; early agents include antibodies to B7-H3

Targets: B7-H3

Bria-TILsRx

Quadrivalent multi-specific binding reagents designed as potent immune cell activators and/or immune checkpoint inhibitors; selectively target and destroy cancer cells while minimizing effects on normal cells; focus on immuno-oncology across multiple cancer types

Targets: B7-H3

Bria-OTS+

Off-the-shelf cellular immunotherapy platform using premanufactured, HLA-matched, genetically modified whole-cell cancer vaccine lines designed to activate innate and adaptive immunity; basis for Bria-MEL+ (melanoma), Bria-PROS+ (prostate cancer), and Bria-OTS (breast cancer) programs.

Capital (as filed)

Cash
$9.9M cash and cash equivalents · Jul 31, 2026 (10-K)
Short-term investments
$10.7M Jul 31, 2026
Operating cash flow
−$7.2M annual ÷ 4, year to Jul 31, 2026 (10-K)
As stated in coverage
$20.5M cash, runway about two quarters from July 31 per the update of Oct 28, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on BriaCell Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-09 Watch BriaCell (BCTX): Scientific Deep Dive for Bria-IMT™ and Pipeline Products Intriguing survival signals but immediate investment thesis dominated by acute financing risk from an open dilutive offering; prudent to wait until financing clears.
  2. 2026-01-14 Watch UPDATE: BriaCell (BCTX) Just Gave Us a Masterclass in Pump and Raise Bankruptcy risk is off the table post-$30M raise but the 100% warrant coverage creates a ceiling at $6.93; wait for the offering to close and flippers to exit before considering entry.
  3. 2026-01-31 Buy speculative UPDATE: BriaCell (BCTX) Drops the Receipts on Super Responders Durability data (47-month super-responders, post-Enhertu activity) upgrades the science score; with bankruptcy risk gone, current weakness in the $5.00–$5.50 range represents a disconnect between value and technical weakness for long-horizon investors.
  4. 2026-02-21 Watch UPDATE: BriaCell (BCTX) – A Safety Nod and a Corporate Shell Game Neither the clean DSMB safety review nor the BriaPro asset shuffle changes the fundamental thesis; the warrant overhang and diluted cap table remain, so waiting for Phase 3 interim data is prudent.
  5. 2026-03-15 Watch UPDATE: BriaCell (BCTX) – The War Chest is Full and AACR is on Deck Post-dilution balance sheet is clean with $29.9M cash and ~four quarters of runway to the Phase 3 interim, but the $6.93 warrant wall still caps near-term upside.
  6. 2026-06-02 Avoid UPDATE: BriaCell (BCTX) — The War Chest Wasn't Full After All A third best-efforts raise in twelve months at a steep discount signals management lacks confidence in near-term catalyst timing; the asymmetric setup that made cautious accumulation defensible no longer holds.
  7. 2026-10-29 Avoid UPDATE: BriaCell (BCTX) - The Clock Moved Again, the Raises Didn't The 1H 2026 interim window passed with no disclosure, runway is roughly two quarters, another raise looks imminent, and governance signals (large salary increases amid going-concern doubt) are moving the wrong way.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 25, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →